(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 15.82% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.06%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Neuropace's revenue in 2026 is $99,986,000.On average, 10 Wall Street analysts forecast NPCE's revenue for 2026 to be $3,396,658,384, with the lowest NPCE revenue forecast at $3,233,373,686, and the highest NPCE revenue forecast at $3,527,959,481. On average, 9 Wall Street analysts forecast NPCE's revenue for 2027 to be $4,227,558,660, with the lowest NPCE revenue forecast at $3,814,128,539, and the highest NPCE revenue forecast at $4,511,034,363.
In 2028, NPCE is forecast to generate $5,274,264,074 in revenue, with the lowest revenue forecast at $4,800,570,115 and the highest revenue forecast at $5,796,775,107.